Skip to main content

Sethera Therapeutics Appoints Biotech Pioneer Dr. Robert Langer to Head and Chair the Scientific Advisory Board and Brigadier General Larry Lunt to Board of Directors

By: Newsfile

Salt Lake City, Utah--(Newsfile Corp. - February 5, 2025) - Sethera Therapeutics announced the appointment of Dr. Robert Langer, a world-renowned scientist, entrepreneur, and co-founder of Moderna, to Head and Chair its Scientific Advisory Board. The company also welcomed Brigadier General Larry V. Lunt, USAF (Ret.), a distinguished leader with decades of strategic expertise, to its Board of Directors.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Scientific Leadership: Dr. Langer's expertise in drug delivery systems and tissue engineering will be invaluable in guiding Sethera's scientific strategy and advancing its pipeline of innovative peptide-based therapeutics.
  • Strategic Leadership: Brig. Gen. Lunt's strategic vision and proven ability to lead organizations through complex challenges will be essential as Sethera continues to grow and evolve.
  • Company's Position Strengthened: The addition of Dr. Langer and Brig. Gen. Lunt to Sethera's leadership team strengthens the company's position in the field of peptide therapeutics. With a focus on accessing complex molecular architectures, Sethera is developing therapies for a wide range of diseases and is poised to make significant contributions to the advancement of human health.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/239712_figure1.png

Click image above to view full announcement.


About Sethera Therapeutics

Sethera Therapeutics is a privately held biopharmaceutical company dedicated to transforming the field of peptide therapeutics. The company's proprietary platform technology enables the development of enzymatically-altered peptide-based therapies with enhanced efficacy, safety, and delivery. The Sethera platform potentially targets a wide range of therapeutic areas. Sethera is building a world-class team and is committed to advancing the field of peptide therapeutics and improving the lives of patients worldwide.

Contacts:

Chelli Miller
219-921-6823
chelli@contentcarnivores.com

Source: Sethera Therapeutics

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239712

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.82
+0.90 (0.43%)
AAPL  265.35
-7.60 (-2.78%)
AMD  198.86
-4.82 (-2.37%)
BAC  49.59
-2.71 (-5.19%)
GOOG  306.65
-0.50 (-0.16%)
META  638.77
-18.24 (-2.78%)
MSFT  392.94
-8.78 (-2.19%)
NVDA  179.59
-5.30 (-2.87%)
ORCL  142.25
-8.06 (-5.36%)
TSLA  399.23
-9.35 (-2.29%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.